As reviewed above, much has been learned over the past 20 years regarding the pathways that KRAS engages and requires during lung tumorigenesis, and specific inhibitors of these downstream signaling ...

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...

Verastem (NASDAQ:VSTM) executives highlighted commercial momentum for the company’s newly launched ovarian cancer therapy and laid out near-term clinical catalysts across its RAS-pathway pipeline ...

SOUTH SAN FRANCISCO, Calif. and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug ...

Researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene or 'oncogene,' and how its activities impact pancreatic cancer outcomes. KRAS ...

Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...

Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 Representative KRAS-directed ...